New Engineered Proteins for Use in Therapy and Vaccine Design

  • J. P. Lecocq
  • M. Courtney
  • E. Degryse
  • S. Jallat
  • M. P. Kieny
  • P. Meulien
  • A. Pavirani
Part of the New Horizons in Therapeutics book series (NHTH)


Protein engineering has opened a new door in biotechnology. With localized mutagenesis of the corresponding DNA, new proteins with altered activity and better stability can be obtained. This new technology has stimulated the imagination of scientists, and in the past few years spectacular results have been obtained.


Human Immunodeficiency Virus Cleavage Site Factor VIII Recombinant Vaccinia Virus Engineer Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams, S. E., Dawson, K. M., Gull, K., Kingsman, S. M., and Kingsman, A. J., 1987, The expression of hybrid HIV:Ty virus-like particles in yeast, Nature 329: 68.PubMedCrossRefGoogle Scholar
  2. Balland, A., Faure, T., Carvallo, D., Cordier, P., Ulrich, P., Foumet, B., De La Salle, H., and Lecocq, J-P., 1988, Characterization of two differently processed forms of human recombinant factor IX synthesized in CHO cells transformed with a polycistronic vector, Eur. J. Biochem. 172: 565–572.PubMedCrossRefGoogle Scholar
  3. Barr, P. J., Steimer, K. S., Sabin, E. A., Parkes, D., George-Nascimento, C., Stephans, J. C., Powers, M. A., Gyenes, A., Van Nest, G. A., Miller, E. T., Higgins, K. W., and Luciw, P. A., 1987, Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae, Vaccine 5: 90.PubMedCrossRefGoogle Scholar
  4. Burke, R. L., Pachl, C., Quiroga, M., Rosenberg, S., Haigwood, N., Nordfang, O., and Ezban, M., 1986, The functional domains of coagulation factor VIII, J. Biol. Chem. 261: 12574–12578.PubMedGoogle Scholar
  5. Cabradilla, C. D., Groopman, J. E., Lanigan, J., Renz, M., Lasky, L. A., and Capon. D. J., 1986. Serodiagnosis of antibodies to the human AIDS retrovirus with a bacterially synthesized env polypeptide, Biol Technol. 4: 128.Google Scholar
  6. Chakrabarti, S., Robert-Guroff, M., Wong-Staal, F., Gallo, R. C., and Moss, B., 1986, Expression of the HTLV-III envelope gene by a recombinant vaccinia virus, Nature 320: 535.PubMedCrossRefGoogle Scholar
  7. Clore, G. M., Sukumaran, D. K., Nilges. M., Zarbock, J., and Gronenborn, A. M.. 1987, The conformations of hirudin in solution: A study using nuclear magnetic resonance, distance geometry and restrained molecular dynamics, EMBO J. 6: 529–537.PubMedGoogle Scholar
  8. Courtney, M., Jallat, S., Tessier, L. H., Benavente, A., Crystal, R. G., and Lecocq, J-P., 1985. Synthesis in E. coli of alphas-antitrypsin variants of therapeutic potential for emphysema and thrombosis, Nature 313: 149–151.PubMedCrossRefGoogle Scholar
  9. Degryse, E., Acker, M., Defreyn, G., Bemat, A., Maffrand, J. P., Roitsch, C., and Courtney, M., 1989, Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin, Protein Engineering 2: 459–465.PubMedCrossRefGoogle Scholar
  10. Dodt, J., Schmitz, T., Schäfer, T., and Bergmann, C., 1986, Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence, FERS Lett. 202: 373–377.Google Scholar
  11. Dodt, J., Seemüller, U., and Fritz, H., 1987, Influence of chain shortening on the inhibitor properties of hirudin and eglin c, Biol. Chem. Hoppe-Seyler 368: 1447–1453.PubMedCrossRefGoogle Scholar
  12. Eaton, D., Rodriguez, H., and Vehar, G. A., 1986a, Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity, Biochemistry 25: 505–512.PubMedCrossRefGoogle Scholar
  13. Eaton, D. L., Wood, W. I., Eaton, D., Hass, P. E., Hollingshead, P., Wion, K., Mather, J., Lawn, R. M., Vehar, G. A., and Gorman, C., 1986b, Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule, Biochemistry 25: 8343–8347.PubMedCrossRefGoogle Scholar
  14. Fortkamp, E., Rieger, M., Heisterberg-Moutses, G., Schweitzer, S., and Sommer, R., 1986, Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech, DNA 5: 511–517.PubMedCrossRefGoogle Scholar
  15. Fulcher, C. A., Roberts, J. R., and Zimmerman, T. S., 1983, Thrombin proteolysis of purified factor VIII procoagulant protein: Correlation with generation of a specific polypeptide, Blood 61: 807–811.PubMedGoogle Scholar
  16. Gitschier, J., Wood, W. I., Goralka, T. M., Wion, K. L., Chen, E. Y., Eaton, D. H., Vehar, G. A., Capon, D. J., and Lawn, R. M., 1984, Characterization of the human factor VIII gene, Nature 312: 326–330.PubMedCrossRefGoogle Scholar
  17. Harvey, R. P., Degryse, E., Stefani, L., Schamber, F., Cazenave, J-P., Courtney, M., Tolstoshev, P., and Lecocq, J-P., 1986, Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis, Proc. Natl. Acad. Sci. USA 83: 1084–1088.PubMedCrossRefGoogle Scholar
  18. Hu, S. L., Kosowski, S. G., and Dalrymple, J. M., 1986, Expression of AIDS virus envelope gene in recombinant vaccinia viruses, Nature 320: 537.PubMedCrossRefGoogle Scholar
  19. Hu, S. L., Kosowski, S. G., and Schaaf, K. F., 1987, Expression of envelope glycoproteins of human immunodeficiency virus by an insect virus vector, J. Virol. 61: 3617–3620.PubMedGoogle Scholar
  20. Jallat, S., Caravallo, D., Tessier, L. H., Roecklin, D., Roitsch, C., Ogushi, F., Crystal, R. G., and Courtney, M., 1986, Altered specificities of genetically engineered arantitrypsin variants, Protein Engineering 1: 29–35.PubMedCrossRefGoogle Scholar
  21. Kieny, M. P., Rautmann, G., Schmitt, D., Dott, K., Wain-Hobson, S., Alizon, M., Girard, M., Chamaret, S., Laurent, A., Montagnier, L., and Lecocq, J. P., 1986, AIDS virus env protein expressed from a recombinant vaccinia virus, Biol Technol. 4: 790.Google Scholar
  22. Lasky, L. A., Groopman, J. E., Fennie, C. W., Benz, P. M., Capon, D. J., Dowbenko, D. J., Nakamura, G. R., Nunes, W. M., Renz, M. E., and Berman, P. W., 1986, Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein, Science 233: 209–212.PubMedCrossRefGoogle Scholar
  23. Loison, G., Findeli, A., Bernard, S., Nguyen-Juilleret, M., Marquet, M., Riehl-Bellon, N., Carvallo, D., Guerra-Santos, L., Brown, S. W., Courtney, M., Roitsch, C., and Lemoine, Y., 1988, Expression and secretion in S. cerevisiae of biologically active leech hirudin, Biol Technol. 6: 72–77.Google Scholar
  24. McCune, J. M., Rabin, L. B., Feinberg, M. B., Lieberman, M., Kosek, J. C., Reyes, G. R., and Weissman, I., 1988, Endoporteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus, Cell 53: 55.PubMedCrossRefGoogle Scholar
  25. McDougal, J. S., Kennedy, M. S., Sligh, J. M., Cort, R. C., Mawie, A., and Nicholson, J. K. A., 1986, Binding of HTLV-III/LAV to T4 + T cells by a complex of the 110 k viral protein and the T4 molecule, Science 231: 382.PubMedCrossRefGoogle Scholar
  26. Meulien, P., Faure, T., Mischler, F., Harrer, H., Ulrich, P., Bouderbala, B., Dott, K., Sainte-Marie, M., Mazurier, C., Wiesel, M.-L., Van de Pol, H., Cazenaze, J.-P., Courtney, M., and Pavirani, A., 1988, A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII, Prot. Engineer. 2: 301–306.CrossRefGoogle Scholar
  27. Pavirani, A., Meulien, P., Harrer, H., Dott, K., Mischler, F., Wiesel, M-L., Mazurier, C., Cazenave, J-P., and Lecocq, J-P., 1987a, Two independent domains of factor VIII co-expressed using recombinant vaccinia viruses have procoagulant activity, Biochem. Biophys. Res. Commun. 145: 234–240.PubMedCrossRefGoogle Scholar
  28. Pavirani, A., Meulien, P., Harrer, H., Schamber, F., Dott, K., Villeval, D., Cordier, Y., Wiesel, ML., Mazurier, C., Van der Pol, H., Piquet, Y., Cazenave, J-P., and Lecocq, J-P., 1987b, Choosing a host cell for active recombinant factor VIII production using vaccinia virus, Biol Technol. 5: 389–392.Google Scholar
  29. Riehl-Bellon, N., Carvallo, D., Acker, M., Van Dorsselaer, A., Marquet, M., Loison, G., Lemoine, Y., Brown, SW., Courtney, M., and Roitsch, C., 1989, Purification and biochemical characterization of recombinant hirudin produced by S. cerevisiae, Biochemistry 28: 2941–2949.PubMedCrossRefGoogle Scholar
  30. Rusche, J. R., Lynn, D. L., Robert-Guroff, M., Langlois, A. J., Lyerly, H. K., Carson, H., Krohn, K., Ranki, A., Gallo, R. C., Bolognesi, D. P., Putney, S. D., and Matthews, T. J., 1987, Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells, Proc. Natl. Acad. Sci. USA 84: 6924–6928.PubMedCrossRefGoogle Scholar
  31. Schapira, M., Ramus, M. A., Jallat, S., Carvallo, D., and Courtney, M., 1986, Recombinant alantitrypsin Pittsburgh (Met Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment, J. Clin. Invest. 77: 635–637.PubMedCrossRefGoogle Scholar
  32. Schapira, M., Ramus, M. A., Waeber, B., Brunner, H. R., Jallat, S., Carvallo, D., Roitsch, C., and Courtney, M., 1987, Protection by recombinant al-antitrypsin Ala357 against arterial hypotension induced by factor XII fragment, J. Clin. Invest. 80: 582–585.PubMedCrossRefGoogle Scholar
  33. Stone, S. R., and Hofsteenge, J., 1986, Kinetics of the inhibition of thrombin by hirudin, Biochemistry 25: 4622–4628.PubMedCrossRefGoogle Scholar
  34. Toole, J. J., Knopf, J. L., Wozney, J. M., Sultzman, L. A., Buecker, J. L., Pittman, D. D., Kaufman, R. J., Brown, E., Shoemacker, C., On, E. C., Amphlett, G. W., Foster, W. B., Coe, M. L., Knutson, G. J., Fass, D. N., and Hewick, R. M., 1984, Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312: 342–347.PubMedCrossRefGoogle Scholar
  35. Toole, J. J., Pittman, D. D., Orr, E. C., Murtha, P., Wasley, L. C., and Kaufman, R. J., 1986, A large region (95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity, Proc. Natl. Acad. Sci. USA 83: 5939–5942.PubMedCrossRefGoogle Scholar
  36. Truett, M. A., Blacher, R., Burke, R. L., Caput, D., Chu, C., Dina, D., Hartog, K., Kuo, C. H., Masiarz, F. R., Merryweather, J. P., Najarian, R., Pachl, C., Potter, S. J., Puma, J., Quiroga, M., Rall, L. B., Randolph, A., Urdea, M. S., Valenzuela, P., Dahl, H. H., Favalaro, J., Hansen, J., Nordfang, O., and Ezban, M., 1985, Characterization of the polypeptide composition of human factor VIII:C and the nucleotide sequence and expression of the human kidney cDNA, DNA 4: 333–349.PubMedCrossRefGoogle Scholar
  37. Vehar, G. A., Keyt, B., Eaton, D., Rodriguez, H., O’Brien, D. P., Rotblat, F., Oppermann, H., Keck, R., Wood, W. I., Harkins, R. N., Tuddenham, E. G. D., Lawn, R. M., and Capon, D. J., 1984, Structure of human factor VIII, Nature 312: 337–342.PubMedCrossRefGoogle Scholar
  38. Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S., and Alizon, M., 1985, Nucleotide sequence of the AIDS virus, LAV, Cell 40: 9–17.PubMedCrossRefGoogle Scholar
  39. Wood, W. 1., Capon, D. J., Simonsen, C. C., Eaton, D. L., Gitschier, J., Keyt, B., Seeburg, P. H., Smith, D. H., Hollingshead, P., Wion, K. L., Delwart, E., Tùddenham, E. G. D., Vehar, G. A., and Lawn, R. M., 1984, Expression of active human factor VIII from recombinant DNA clones, Nature 312: 330–337.Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • J. P. Lecocq
    • 1
  • M. Courtney
    • 1
  • E. Degryse
    • 1
  • S. Jallat
    • 1
  • M. P. Kieny
    • 1
  • P. Meulien
    • 1
  • A. Pavirani
    • 1
  1. 1.Transgene S.A.Strasbourg CedexFrance

Personalised recommendations